{"id":"NCT01454934","sponsor":"Eisai Inc.","briefTitle":"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-12-09","primaryCompletion":"2014-05-30","completion":"2016-05-02","firstPosted":"2011-10-19","resultsPosted":"2017-03-01","lastUpdate":"2023-06-22"},"enrollment":540,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-Small Cell Lung Cancer (NSCLC)"],"interventions":[{"type":"DRUG","name":"Eribulin","otherNames":[]},{"type":"DRUG","name":"TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed","otherNames":[]}],"arms":[{"label":"Arm A","type":"EXPERIMENTAL"},{"label":"Arm B","type":"ACTIVE_COMPARATOR"}],"summary":"This is a randomized, open-label, multicenter, Phase 3 study, comparing efficacy and safety of eribulin with TPC in subjects with advanced and disease progression following at least two prior regimens for advanced disease, which should have included a platinum-based regimen.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Randomization (Day 1) until date of death from any cause, or 37 months","effectByArm":[{"arm":"Arm A: Eribulin Mesylate","deltaMin":9.5,"sd":null},{"arm":"Arm B: Vinorelbine, Gemcitabine, Docetaxel, or Pemetrexed","deltaMin":9.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1343"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":83,"countries":["United States","Australia","France","Germany","Hong Kong","Italy","Japan","Poland","Russia","Singapore","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["28911085"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":96,"n":269},"commonTop":["Neutropenia","Decreased appetite","Nausea","Anaemia","Fatigue"]}}